Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OTOJV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LCB73
|
|||||
| Synonyms |
LCB73; IKS03; NI-2201
Click to Show/Hide
|
|||||
| Organization |
Light Chain Bioscience (Originator);LCB;Iksuda Therapeutics
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD19 antibody
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
PBD dimer
|
Payload Info | ||||
| Therapeutic Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
β-glucuronide trigger linker
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Diffuse large b-cell lymphoma |
1 Trials
|
||||||||
| Follicular lymphoma |
1 Trials
|
||||||||
| Mantle cell lymphoma |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants (≥18 years) include: Part 1 - B-cell NHL patients (excluding specific subtypes) with optional CD19 confirmation; Part 2 - confirmed CD19+ B-cell NHL (DLBCL, FL, MCL, etc.) requiring biopsy for complete response verification. All patients must have relapsed/refractory disease (≥2 prior therapies), ECOG 0-1, life expectancy ≥10 weeks, and meet contraception requirements. Part 1 allows non-measurable disease with optional biopsy; Part 2 requires measurable disease (Lugano criteria) and mandatory biopsy.
Click to Show/Hide
|
||||
| Administration Dosage |
Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05365659 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas (NHL) | ||||
| Primary Endpoint |
The study will determine the Recommended Dose for Expansion (RDE) in Part 1 (up to 20 months) based on DLTs and comprehensive safety data. Part 2 will assess Objective Response Rate (up to 42 months) using The Lugano Classification (Cheson 2014) for response evaluation.
|
||||
| Other Endpoint |
Immunogenicity of IKS03 (Parts 1-2) will be evaluated through ADA measurements in serum (up to 42 months). Pharmacokinetic analysis will characterize IKS03 plasma concentrations throughout the study period. The recommended Phase 2 dose (RP2D) will be determined based on antitumor activity, tolerability, and target plasma concentration achievement (up to 42 months).
Click to Show/Hide
|
||||